Loading organizations...
§ Private Profile · Tel Aviv, Israel
Scala Biodesign is a technology company.
Scala Biodesign operates an advanced protein engineering platform designed to create superior proteins. The company integrates principles of evolution, physics, and artificial intelligence to precisely and rapidly develop high-performance proteins, aiming to improve their stability and efficiency for diverse applications.
The company was founded by Dr. Ravit Netzer, who serves as CEO, and Dr. Adi Goldenzweig, the CTO. Their partnership emerged from extensive research into the complex challenges inherent in protein engineering. Both bring a scientific pedigree that underpins their approach to developing a novel and automated platform for protein design.
Leading pharmaceutical and chemical companies utilize Scala Biodesign’s technology. The firm’s long-term vision centers on designing proteins with enhanced speed and accuracy, thereby accelerating product development cycles and increasing success rates across various industries that rely on engineered proteins.
Scala Biodesign has raised $6.0M across 1 funding round.
Scala Biodesign has raised $6.0M in total across 1 funding round.
Scala Biodesign has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in September 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2023 | $6M Seed | TLV Partners | Altair Capital Management, Amino Capital, Flashpoint VC, Flex Capital, Inovia Capital, Journey Ventures, Locus Ventures, Matrix Capital, Bobby Goodlatte, SUE XU | Announced |
Scala Biodesign has raised $6.0M in total across 1 funding round.
Scala Biodesign's investors include TLV Partners, Altair Capital Management, Amino Capital, Flashpoint VC, Flex Capital, iNovia Capital, Journey Ventures, Locus Ventures, Matrix Capital, Bobby Goodlatte, Sue Xu.
Scala Biodesign is a Tel Aviv-based biotechnology company specializing in computational protein design, using AI, physics-based modeling, and biological data analysis to engineer superior proteins such as antibodies, enzymes, and vaccine immunogens.[1][2] It serves pharmaceutical, chemical, biotech, foodtech, and sustainability industries by improving protein stability, activity, half-life, thermal stability, and expression levels, enabling faster development of therapeutics, vaccines, affordable food products, and sustainable manufacturing processes at reduced time and cost.[1][2][3] Founded in 2022, the company launched with $5.5 million in seed funding led by TLV Partners, demonstrating early growth momentum through commercial applications of its PROSS algorithms and partnerships with pharmaceutical firms.[2]
Scala Biodesign was founded in 2022 by Ravit Netzer (CEO) and Dr. Adi Goldenzweig (CTO), who developed its core PROSS algorithms during their PhD studies at Israel's Weizmann Institute of Science.[2] Their research focused on redesigning natural proteins to enhance properties like stability and expression, laying the foundation for the company's one-shot computational platform.[2][4] The idea emerged from recognizing proteins' central role in therapeutics, vaccines, food, and industrial processes, with early traction coming from commercial use of PROSS and ongoing projects with pharmaceutical companies, culminating in a $5.5M seed round at launch.[2]
Scala Biodesign rides the wave of AI-powered synthetic biology and protein engineering, a trend accelerating drug discovery, biomanufacturing, and sustainability amid rising demand for precise, customizable biologics.[1][2] Timing is ideal post-AlphaFold's protein structure predictions, which de-risk computational design; market forces like billions spent annually on protein R&D and needs for faster, greener therapeutics favor its tools.[2] By democratizing protein optimization, it influences the ecosystem, enabling smaller biotechs and non-pharma firms to innovate, much like how Cradle and Biomatter expand ML-driven design, potentially disrupting chemical and pharma sectors.[1][2]
Scala Biodesign is poised to scale through deeper pharma integrations and expansion into foodtech/sustainability, leveraging its PROSS edge amid surging AI-bio investments.[2] Trends like multimodal AI models and lab-data integration will boost its platform, while regulatory tailwinds for biologics amplify growth; expect Series A funding and more partnerships soon, evolving it into a core enabler for protein-centric innovation.[1][2] This positions Scala as a key player in transforming proteins from research hurdles to commercial realities, echoing its launch promise of revolutionizing biotech efficiency.[2]